At least two key drugs in the gliptin category have already gone off patent and cheaper variants are crowding the market. Also, several patent expiries are round the corner for the newest category......
A recent report has suggested that future patent expires in the cardiac and anti-diabetes space would form a good opportunity for smaller firms, given their franchise in these segments. The next......
Markets closed lower for the third straight day with IT giant TCS leading the fall after its Q2 results missed street expectations while lower dollar revenue guidance from Infosys on Monday also......
Import alert on Ranbaxy’s Mohali unit; Strides’ injectible arm gets warning letter Indian drug makers have again come under the scrutiny of the US Food and Drug Administration (US FDA),......
A Union health ministry probe has revealed that pharmaceutical majors conducting clinical trials in India have not given compensation to majority of the volunteers who died during the trials.Of the......